Skip to main content
RPRX
NASDAQ Life Sciences

Royalty Pharma Raises 2026 Portfolio Receipts Guidance to $3.50-$3.55B on 9% Q3 Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$66.4
Mkt Cap
$38.273B
52W Low
$36.027
52W High
$67.705
52W Position info
84% above low
Off High info
1.9% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

RPRX sits 84% above its 52-week low of $36.027.

Summary

Royalty Pharma raised full-year 2026 Portfolio Receipts guidance to $3,500-$3,550 million after 9% third-quarter growth, while booking a $150 million non-cash impairment on pelacarsen.


Key Events · Earnings and Guidance · RPRX

  • Guidance Raised for Full Year 2026

    Portfolio Receipts guidance lifted to $3,500-$3,550 million from $3,400-$3,500 million, implying 10%-11% Royalty Receipts growth.

  • Q3 Portfolio Receipts Up 9%

    Portfolio Receipts rose to $890 million from $814 million, with Royalty Receipts of $883 million driven by Tremfya, Voranigo, Evrysdi and Imdelltra.

  • $150 Million Pelacarsen Impairment

    A non-cash impairment was recorded after Novartis's Phase 3 Lp(a)HORIZON trial of pelacarsen missed its primary endpoint; GAAP net income fell to $145 million from $284 million.

  • Cash Generation and Capital Returns

    Net cash from operations was $686 million and Portfolio Cash Flow $673 million; the company paid $135 million in dividends and repurchased about 1.5 million shares for $87 million in the quarter.


Analysis · RPRX · Life Sciences

Royalty Pharma beat its own trajectory and lifted full-year Portfolio Receipts guidance to $3,500-$3,550 million from $3,400-$3,500 million, with Q3 Portfolio Receipts up 9% to $890 million and Royalty Receipts up 9% to $883 million. The quarter was not clean: a $150 million non-cash impairment on pelacarsen followed Novartis's Phase 3 Lp(a)HORIZON miss, and GAAP net income fell to $145 million from $284 million a year earlier on that charge and higher operating costs. Cash generation remains the core of the story, with $686 million from operations and $673 million of Portfolio Cash Flow funding the dividend and buybacks. The raised guidance excludes any contribution from future transactions, so the $1.9 billion of announced deals this year is upside not yet in the numbers.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RPRX was trading at $66.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $36.03 to $67.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RPRX - Latest Insights

RPRX
Nov 04, 2026, 9:03 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $66.20
Real-time Price: $67.87 info
Change: +$1.67 (+3%) info
Market Cap: $38.934B info
RPRX
Nov 04, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $66.58
Real-time Price: $67.87 info
Change: +$1.29 (+2%) info
Market Cap: $38.934B info
RPRX
Aug 12, 2026, 5:23 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $59.22
Real-time Price: $67.87 info
Change: +$8.65 (+15%) info
Market Cap: $38.934B info
RPRX
Aug 05, 2026, 9:02 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $57.69
Real-time Price: $67.87 info
Change: +$10.18 (+18%) info
Market Cap: $38.934B info
RPRX
Aug 05, 2026, 7:56 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $58.62
Real-time Price: $67.87 info
Change: +$9.25 (+16%) info
Market Cap: $38.934B info